Drug intelligence / Profile preview

Zeldana

Development stage
Unknown
Lead developer
Misemer Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Zeldana is a prescription-grade dietary supplement developed by Misemer Pharmaceutical, specifically formulated to provide comprehensive nutritional support. It is an oral multivitamin and mineral supplement that includes bioavailable forms of essential nutrients, such as levomefolate calcium (L-methylfolate), methylcobalamin (Vitamin B12), and cholecalciferol (Vitamin D3). Zeldana is indicated for the clinical management of patients with specific nutritional requirements that cannot be met through normal diet alone, often used under medical supervision to address deficiencies or increased physiological demands. Its mechanism of action involves the exogenous replenishment of micronutrients that serve as essential cofactors for metabolic enzymes, support cellular DNA synthesis and repair, and maintain systemic homeostasis. The inclusion of L-methylfolate is particularly significant as it bypasses the metabolic steps required for the activation of folic acid, making it suitable for patients with genetic polymorphisms in the MTHFR enzyme.

Brand names
Zeldana
02

Targets

RAR (Retinoic acid receptor)TFRC (Transferrin Receptor)VDR (Vitamin D receptor)1C metabolism (One-carbon metabolism)Nucleotide synth (Nucleotide synthesis enzymes)SLC superfamily (Solute carrier superfamily)

Beyond the preview

Go deeper on Zeldana.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zeldana.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call